Overview: Phospholipase A2 Receptor Quantitative Antibody TestIntroduction: The Phospholipase A2 Receptor Quantitative Antibody Test quantifies PLA2R antibodies to diagnose kidney disease, causing proteinuria or edema. Aligned with 2023 NKF guidelines, it uses immunoassays for high specificity, supporting renal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected membranous nephropathy.
Other Names: PLA2R Quant Assay, Quantitative Membranous Nephropathy Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: PLA2R antibody testing began in the 2000s with membranous nephropathy research. Quantitative methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Quantifies PLA2R antibodies to diagnose kidney disease, guides treatment, and evaluates patients with proteinuria or edema.
Test Parameters: 1. PLA2R Antibody Level
Pretest Condition: No fasting required. Collect serum or saliva. Report history of proteinuria, edema, or renal symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document proteinuria, edema, or history of kidney disease. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, kidney disease implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to quantify PLA2R antibody levels. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for kidney disease diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Elevated PLA2R antibody levels confirm membranous nephropathy, guiding immunosuppressive therapy. Normal levels may require kidney biopsy.
Specialist Consultation: Consult a nephrologist for result interpretation and treatment planning.
Additional Supporting Tests: Kidney biopsy, urine protein electrophoresis, or anti-PLA2R qualitative testing to confirm kidney disease diagnosis.
Test Limitations: Non-specific for certain kidney diseases; clinical correlation is needed. Sample quality affects sensitivity.
References: NKF Kidney Guidelines, 2023; Kidney International, Beck LH, 2022.
